company background image
INAF logo

Indofarma IDX:INAF Stock Report

Last Price

Rp140.00

Market Cap

Rp433.9b

7D

-6.0%

1Y

-78.1%

Updated

21 Jun, 2024

Data

Company Financials

INAF Stock Overview

Engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally.

INAF fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

PT Indofarma Tbk Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Indofarma
Historical stock prices
Current Share PriceRp140.00
52 Week HighRp725.00
52 Week LowRp130.00
Beta-0.074
11 Month Change-51.39%
3 Month Change-67.89%
1 Year Change-78.13%
33 Year Change-94.59%
5 Year Change-93.86%
Change since IPO-31.71%

Recent News & Updates

Recent updates

Shareholder Returns

INAFID PharmaceuticalsID Market
7D-6.0%0.1%1.7%
1Y-78.1%-23.1%1.1%

Return vs Industry: INAF underperformed the ID Pharmaceuticals industry which returned -22.5% over the past year.

Return vs Market: INAF underperformed the ID Market which returned 0.5% over the past year.

Price Volatility

Is INAF's price volatile compared to industry and market?
INAF volatility
INAF Average Weekly Movement14.1%
Pharmaceuticals Industry Average Movement7.3%
Market Average Movement5.8%
10% most volatile stocks in ID Market12.9%
10% least volatile stocks in ID Market2.6%

Stable Share Price: INAF's share price has been volatile over the past 3 months.

Volatility Over Time: INAF's weekly volatility has increased from 9% to 14% over the past year.

About the Company

FoundedEmployeesCEOWebsite
19181,086- Yeliandrianiindofarma.id

PT Indofarma Tbk, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. It offers laboratory, pharmaceutical, and health equipment; orthopedic and prosthetic equipment; industrial machinery for packaging, bottling, and canning; provides health consultancy services; and trades in laboratory equipment, pharmacy, and medicines. The company serves medicine product, medical and dental equipment, electromedical and electrotherapy equipment, herbal processing, and tea processing industries, as well as furniture industry for operations, medical care, and dental care.

PT Indofarma Tbk Fundamentals Summary

How do Indofarma's earnings and revenue compare to its market cap?
INAF fundamental statistics
Market capRp433.90b
Earnings (TTM)-Rp437.05b
Revenue (TTM)Rp684.91b

0.6x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INAF income statement (TTM)
RevenueRp684.91b
Cost of RevenueRp867.00b
Gross Profit-Rp182.08b
Other ExpensesRp254.97b
Earnings-Rp437.05b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-141.02
Gross Margin-26.58%
Net Profit Margin-63.81%
Debt/Equity Ratio-728.4%

How did INAF perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.